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Abstract In this work, false positive rate of an arrayCGH
platform for its use in day-3 single-blastomere analysis was
calculated. For this purpose, 38 embryos diagnosed as abnor-
mal on day-3 by FISH were re-biopsied on day-4. Single-cell
day-4 arrayCGH diagnosis was then performed. A successful
amplification was obtained in 97.4 % (37/38) of the day-4
cells analysed by arrayCGH. Day-3 FISH and day-4
arrayCGH diagnosis were concordant in 35/37 cases. The
two discordant embryos were spread and all the cells from
each embryo were re-analysed by FISH on day 5. The same
error rate (2.7 %) for day-3 FISH and day-4 arrayCGH was
obtained when comparing day-5 FISH re-analysis. After this
pre-clinical phase, the platform was used for day-3 arrayCGH
clinical application in 320 patients (1,760 embryos). Day-3
amplification rate was 98.6 %. An optimal reproductive out-
come was obtained when applying arrayCGH to a clinical
program: clinical pregnancy rate per cycle of 38.4 % and
60.3 % per transference were obtained, with an implantation
rate of 53.5 %. Overall miscarriage rate was 10.6 %.
Additionally, day-5 FISH re-analysis was performed in 42 of
the embryos from the clinical phase, obtaining a concordance
rate of 97.6 % with day-3 arrayCGH.
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Introduction
Preimplantation Genetic Aneuploidy Screening (PGS) is
offered in many IVF centres to improve the reproductive
outcome of specific groups of patients. In particular, PGS
programs have widely employed fluorescence in situ
hybridisation (FISH) for screening numerical chromosome
anomalies in preimplantation embryos. Using this technique
on single day-3 blastomeres has led to reported improve-
ments in implantation and pregnancy rates in retrospective
studies of cases of advanced maternal age (AMA), severe
male factor (SMF) infertility, and recurrent miscarriage
(RM); the benefit of this analysis in couples with repetitive
implantation failure (RIF) has been more controversial [14].
Interestingly, a meta-analysis of the randomized control
trials (RCT) conducted in PGS indicated that FISH screen-
ing does not improve live birth rates in IVF patients and,
indeed, lowers live birth rates in AMA patients [11].
However, the results reported in these RCTs were attributed
to several methodological flaws [2, 16, 20, 22] and, more
recently, to the poor predictive value of day-3 FISH [18].
Capsule False positive rate of an arrayCGH platform was calculated
for single-blastomere analysis, resulting in high efficiency and
accuracy of the platform. Furthermore, an optimal reproductive
outcome was obtained when applied to a clinical program.
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Another complication of PGS is the time of biopsy. The
most common option has been day-3 embryo biopsy, but
this approach has been criticized arguing a reduction in
embryo viability due to the biopsy; in fact, a defective
biopsy could damage the embryo [22]. Further, embryo
mosaicism at cleavage stage and self-correction of aneuploi-
dies between cleavage stage and blastocyst stage have been
noted [6]. Recent studies, however, suggest that both phe-
nomena may be overestimated by day-3 FISH analysis [23,
29]. To avoid any kind of misdiagnosis due to embryo
mosaicism, polar bodies biopsies have been used [27], but
in those cases, only maternal genetic information is
obtained, thus all the paternal contribution as well as the
mitotic errors are missed. The third option is to biopsy
trophectoderm cells from blastocysts, considered less inva-
sive and with a high concordance between inner cell mass
and trophectoderm cells [1, 18].
Previous RCTs have been limited by the technique avail-
able for chromosomal analysis. Using a sequential FISH
protocol, only a selected panel of chromosomes, usually
between 9 and 12, could be analyzed simultaneously.
Additionally, the technique required cell fixation on a mi-
croscope slide. Poor spreading could result in low-quality
nuclei or even loss of chromatin with impairment on the
accuracy of the diagnosis [17, 26]. Indeed, misdiagnosis can
also result from overlapping signals, split signals, cross-
hybridisation, or polymorphisms [5]. However, some of
these limitations might be overcome by using different
strategies. For example, to improve FISH accuracy, addi-
tional probes could be incorporated to double-check for
dubious signals and false monosomies for certain chromo-
somes [3, 5, 10, 15, 19, 25]. Indeed, higher diagnosis
accuracy was obtained when performing these additional
hybridisation rounds comparing with embryos in which no
re-hybrisation rounds were used (95 % vs. 82.7 %; p0
0.0443) [15]. Despite this improvement, the limitation on
the number of tested chromosomes remained.
Recently, several approaches toward 24-chromosome anal-
ysis have been developed to improve clinical results by incor-
porating comprehensive chromosomal screening. These
approaches require whole-genome amplification (WGA) to
generate enough DNA for analysis. The first of these
approaches applied to PGS was comparative genomic hybrid-
isation (CGH) [28], in which the genome of interest is hybrid-
ized against a reference genome in a slide containing a
spreading of euploid human metaphases. More recently,
arrayCGH has emerged, providing higher resolution and more
rapid and automated diagnosis. This approach uses microarray
slides containing DNA spots representative of the human
genome. Two types of array platforms have been described
in PGS: arrayCGH and SNParray. In arrayCGH platforms the
spots can be clones of bacterial artificial chromosomes (BAC-
arrayCGH) or synthetic oligonucleotides (oligo-arrayCGH).
In SNParray platforms, spots include SNPs (Single
Nucleotide Polymorphisms) from all the genome and add to
the 24-chrosomsome analysis the possibility of haplotyping
the sample [8]. These advances based on array platforms, offer
the opportunity to increase the reliability and standardisation
of diagnosis for PGS, but the approaches need to be optimized
for clinical use.
In this study, we sought to evaluate the potential of a single-
cell adapted BAC-based arrayCGH platform for the detection
of aneuploidies in cleavage stage embryos. A single blasto-
mere from embryos previously diagnosed as abnormal by
day-3 FISH in our routine PGS program was analysed by
arrayCGH on day 4. Both diagnoses were then compared
and, in cases of discordant results, the remaining cells of the
embryo were fixed on day 5 and re-analysed by FISH. After
this pre-clinical study, the same platform was applied to an
initial set of patients who underwent day-3 arrayCGH diag-
nosis. Clinical results of these PGS cycles are presented.
Materials and methods
This prospective study was performed from October 2009 to
March 2012. The pre-clinical phase of the study was per-
formed from October 2009 to February 2010; subsequently,
arrayCGH was applied clinically.
Clinical protocol for PGS cycles by FISH
In our routine PGS program, all patients with a specific
clinical indication for PGS signed a specific informed consent
before undergoing PGS. Standardized ovarian stimulation
protocols were used and intracytoplasmic sperm injection
was performed in all cases. Fertilization was assessed 17–
20 h after microinjection, and embryo cleavage was recorded
every 24 h. Embryos were grown in IVF/CCM medium (1/1)
(Vitrolife, Göteborg, Sweden) until day 3, when embryo bi-
opsy was performed. Subsequently, embyos were cultured in
CCM medium with a monolayer of endometrial epithelial
cells until day 5 [12].
For biopsy, embryos were placed on a droplet containing a
Ca2+/Mg2+-free medium (G-PGD, Vitrolife, Göteborg,
Sweden), and the zona pellucida was perforated using acid
Tyrode’s solution or laser technology (OCTAX, Herbron,
Germany). A single blastomere was removed in embryos with
≥5 nucleated blastomeres and ≤25 % of fragmentation degree.
Individual blastomeres were fixed on glass slides under an
inverted microscope, using a slightly modified Tarkowski’s
protocol with methanol-acetic acid (3:1) solution. FISH diag-
nosis included the analysis of nine chromosomes in two con-
secutive rounds of hybridisation: in the first round
chromosomes 13, 16, 18, 21, and 22 were analysed using
MultiVysionTM PB panel; in the second round chromosomes
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15, 17, X, and Ywere analysed usingMultiVysionTM 4 Colour
Custom panel (Vysis, Inc., Downers Grove, IL, USA).
Additionally, re-hybridisation rounds using additional probes
were conducted to rescue non-informative or monosomic
results as previously described [15]. Chromosomally normal
embryos were transferred on day 5, and the surplus euploid
embryos cryopreserved.
Pre-clinical phase
In the pre-clinical phase, 38 embryos diagnosed on day 3 as
chromosomally abnormal by FISH were re-biopsied on day 4.
A second cell from each one of these embryos was biopsied
and analysed by arrayCGH on day 4. It was known prior to
arrayCGH analysis that the sample came from an embryo
known to have been given an aneuploid diagnosis by FISH.
Then, comparison of both diagnoses was then performed. In
cases of discordant results, day-5 re-analysis of the remaining
cells of the embryo was performed by FISH using probes for
the discordant chromosomes (Fig. 1).
To perform day-4 arrayCGH analysis, a single cell from
each embryo was amplified using SureplexTM DNA amplifi-
cation system (BlueGnome, Cambridge, UK). Amplification
quality was ensured by gel electrophoresis (Lonza, Rockland,
USA). Then, sample and control DNAwere labelled with Cy3
and Cy5 fluorophores, respectively. Labelling mixes were
combined and hybridised on a 24sure array (BlueGnome,
Cambridge, UK) for 6 to 12 h. Final results were obtained
on early day 5 using a laser scanner (710 Innoscan, Innopsys,
Carbonne, France; and Powerscanner, TECAN, Männedorf,
Switzerland). BlueFuse software was used to analyse data
(BlueGnome, Cambridge, UK). Analysis by arrayCGH was
completed in a 24-h protocol.
In cases of discordant results between day-3 FISH and day-4
arrayCGH, the remaining cells of the day-5 embryo were fixed
and re-analysed by FISH using probes directed to the discor-
dant chromosomes. Due to the limited number of chromo-
somes that can be analysed simultaneously, day-5 FISH
diagnoses were performed with knowledge of the chromo-
somes involved in the aneuploidies previously seen on day-3
and day-4, but without knowing what aneuploidies for these
chromosomes were. Day-5 embryos were fixed using a slightly
modified fixation method described in [9]. After removing
zona pellucida with Tyrode’s acid, day-5 embryos were placed
in a Ca2+/Mg2+ free medium (G-PGD, Vitrolife, Göteborg,
Sweden). Then, the whole embryo was fixed using a spreading
solution with 0.010 NHCl and Tween 20; when cytoplasmwas
dissolved, nuclei were re-fixed with methanol-acetic acid.
Clinical application of arrayCGH
After the pre-clinical evaluation of the platform, patients
coming to our PGS program were offered the possibility of
undergoing day-3 PGS by arrayCGH instead of by FISH. A
total of 320 patients decided to undergo PGS by day-3
arrayCGH in these two-year clinical experience (March
2010–March 2012). The number of patients for each PGS
indication was: 106 for AMA, 96 for RM, 62 for RIF, 28 for
severe male factor (SMF), and 28 patients with a previous
chromosomally abnormal gestation as a principal indication
for PGS. RM indication included patients with at least 2
miscarriages, RIF patients with three or more previous IVF
attempts failed, and SMF patients with seminal parameters
severely affected. PGS was indicated for AMA, in patients
over 38 years old until May 2010. After that, the AMA
group was re-defined as patients over 40 years old due to
a retrospective analysis of the results from our lab [13]. Also
mixed indications were found in 47 of those 320 couples, in
which AMA was the secondary indication for 22 RM cou-
ples, 14 RIF couples and 7 couples with a previous chro-
mosomally abnormal gestation.
On day 3, a single blastomere was biopsied in the 1,760
embryos, and single-cell arrayCGH was performed using
Day-3 FISH
38 abnormal 
embryos
Day-4 
arrayCGH
Day-5 FISH 
re-analysis
Day-3 Embryo biopsy
Concordant Discordant
Euploid 
embryos
Day-5 Transfer / 
Cryopreservation
Fig. 1 Workflow of the validation phase. After performing our routine
day-3 FISH program, a second cell was biopsied on day 4 in 38 embryos
diagnosed as chromosomally abnormal. Single-cell arrayCGH diagnosis
was performed in those samples. Day-3 FISH and day-4 arrayCGH
diagnoses were compared, and, in cases of discordant results, the whole
day-5 embryo was fixed to be re-analysed by FISH using probes directed
to the discordant chromosomes
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the same 24-h protocol used in the validation phase.
ArrayCGH protocol started in the following morning, and
results were obtained on early day-5. Chromosomally nor-
mal embryos were transferred on day 5 of the corresponding
cycle and the surplus chromosomally normal embryos were
cryopreserved.
Re-analysis of the results of the clinical application phase
No special criteria in the selection of day-5 embryos for re-
analysis were followed. The only limitation to include abnor-
mal embryos in this study was their availability in the
corresponding IVF units. We requested aneuploid embryos
independtly of the affected chromosome, since we dispose
FISH-probes for all the chromosomes. After all, 42 embryos
diagnosed as chromosomally abnormal by arrayCGH in the
clinical phase were spread and fixed to be re-analysed by
FISH on day 5, using probes directed to the abnormal chro-
mosomes. In these embryos, the same fixation protocol de-
scribed in the validation phase was applied (Figs. 2 and 3).
Results
In the pre-clinical phase, a second cell was biopsied on day
4 from 38 embryos diagnosed as abnormal by FISH on day
3. A successful single-blastomere amplification was
obtained in 37/38 cells (97.4 %). Each of the 37 products
of amplification produced an interpretable arrayCGH result.
In 35/37 of those blastomeres (94.6 %), day-4 arrayCGH
confirmed day-3 FISH diagnosis: In 62.9 % of them (22/35),
arrayCGH showed only the same aneuploidies observed by
FISH; while in the remaining 37.1 % (13/35), additional
aneuploidies were observed by arrayCGH for chromosomes
not tested by FISH. The two remaining embryos (5.4 %)
exhibited discordant FISH and arrayCGH results; these em-
bryos were re-analysed by FISH on day 5 (Table 1). One of
them was diagnosed as tetraploid by FISH on day 3, but as
46, XY by arrayCGH. This embryo was arrested on day 5,
and the 6 cells of the embryo were determined to be tetra-
ploid by day-5 FISH. Thus, day-3 FISH diagnosis was
confirmed in this embryo. The second discordant embryo
showed monosomy 16 and trisomy XXY by day-3 FISH,
but was diagnosed as 47,XY+3 by arrayCGH. The whole
blastocyst was fixed on day 5, and 68 cells were analysed by
FISH for chromosomes 3, 16, X, and Y. In this case, the day-
4 arrayCGH result was confirmed in the whole blastocyst.
Regarding the type of abnormalities observed in those 37
embryos, the most common ones were chromosome loss
(n067), followed by chromosome gain (n038). Of those
106 aneuploidies, 49 (46.2 %) were for chromosomes not
analysed by FISH.
In the clinical phase of the study, a successful amplifica-
tion was obtained in 1,736 out of 1,760 blastomeres
(98.6 %). A total of 1,289 embryos were diagnosed as
abnormal (74.2 %) by arrayCGH. Of those abnormal em-
bryos, 262 (20.3 %) were diagnosed as chaotic, showing a
complex pattern of aneuploidies. Excluding chaotic embry-
os, 31.6 % (325/1027) of the remaining abnormal embryos
exhibited aneuploidies only for the 9 chromosomes analysed
in our FISH program; 40.4 % (415/1027) had aneuploidies
for the typically-assessed chromosomes as well as for other
chromosomes; and 28 % (287/1027) of them had aneuploi-
dies only for chromosomes different from the 9 analysed in
our FISH program.
Day-5 FISH re-analysis of the abnormal embryos from the
clinical phase of the study showed 97.6 % (41/42) concor-
dance with day-3 arrayCGH diagnosis. The discordant em-
bryo was diagnosed as 47,XX,+15 by arrayCGH on day 3, but
FISH analysis of the whole embryo on day 5 detected the
following abnormalities: 2n,XX in 22 cells; 4n,XXXX in 2
cells; and 48,XX,+13,+21 in one cell.
Concerning the reproductive outcome of the 230 day-3
arrayCGH cycles, chromosomally normal embryos were
available for transfer in 204 cycles (63.7 %). A clinical
pregnancy was observed in 123 patients (38.4 % per cycle;
60.3 % per transference), with an implantation rate of
53.5 % (161 sacs/301 transferred embryos). Thirteen mis-
carriages were observed (10.6 %); consequently, successful
rates of ongoing pregnancy (33.1 % per cycle; 52 % per
transference) and of ongoing implantation rate (47.8 %)
were obtained. These results are described in Table 2
according to maternal age. Only in three of these miscar-
riages an hysteroembryoscopy could be performed, and all
of them were chromosomally normal (one case was a geme-
lar gestation with 46,XY karyotype, while the other two
miscarriages were 46,XX).
Euploid 
embryos
42 abnormal
embryos
Day-3 Embryo biopsy
Day-3 arrayCGH
Day-5 Transfer / 
Cryopreservation
Day-5 Embryo fixation: 
FISH re-analysis
Fig. 2 Workflow of the clinical phase. Day-3 arrayCGH diagnosis was
performed on single blastomeres. Euploid embryos were transferred or
cyropreserved on day 5. To determine accuracy, 42 embryos diagnosed
as chromosomally abnormal on day 3 were re-analysed by day-5 FISH
using probes directed to the altered chromosomes
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Fig. 3 Images of one of the two discordant cases of the validation phase.
Day-3 FISH show 4 signals for each chromosome: red colour for chromo-
some 13, Aqua for 16, Blue for 18, Green for 21 and Gold for 22 (Multi-
VysionTM PB panel, Vysis, Inc., Downers Grove, IL, USA), meaning it was
a tetraploid cell. However, day-4 arrayCGH show a euploid pattern, and
finally day-5 FISH using the same probes used on day 3 corroborate FISH
diagnosis at cleavage stage. It is worth mentioned that as it was an arrested
embryo on day-5, only 6 cells could be re-analysed
Table 1 Comparison of discordant results obtained between day-3
FISH and day-4 arrayCGH diagnosis. In one case, day-3 FISH diag-
nosis was confirmed by day-5 FISH re-analysis; in the other, day-4
arrayCGH diagnosis was confirmed
Day-3 FISH Day-4 arrayCGH Day-5 FISH re-analysis
tetraploid 46,XY tetraploid (6 cells)a
monosomy 16,
trisomy XXY
47,XY+3 47,XY+3 (68 cells)a
a Only chromosomes involved in the aneuploidies previously observed
were tested for Day-5 FISH re-analysis
Table 2 Clinical results of day-3 PGS by arrayCGH, divided into two
age groups: patients up to 40 years old and patients over 40
≤40 years >40 years Total
No. of cycles 232 88 320
Mean age (SD) 36.3 (3.0) 42.0 (1.1) 37.9 (3.7)
% Embryo transfers 73.3 38.6 63.7
% Abnormal embryos 68.3 88.1 73.6
Pregnancy rate/transfer 58.2 67.6 59.8
Pregnancy rate/cycle 42.7 26.1 37.5
Implantation rate 51.3 63.0 53.5
Miscarriage rate 12.1 3.4 10.6
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Discussion
This study is focused on the evaluation of a BAC-based
array CGH platform for aneuploidy detection in cleavage
stage embryos and in the subsequent clinical application of
this platform. In the pre-clinical phase of the study, the
platform was able to detect those aneuploidies found by
FISH on day 3. Moreover, arrayCGH detected additional
aneuploidies for chromosomes not analysed by FISH, and
the error rate for both techniques was the same (2.7 %). This
error rate is in accordance with other validation studies
performed using array platforms for PGS [4, 7, 24].
Two discordant results between day-3 FISH and day-4
arrayCGH were observed in the pre-clinical phase. Day-5
FISH re-analyses of the whole embryo indicated that: one
case could have been a day-3 FISH misdiagnosis, because
all cells on day 5 exhibited the chromosomal abnormality
detected by day-4 arrayCGH instead of the one detected by
day-3 FISH; while the second case could be explained as a
day-4 arrayCGH misdiagnosis, likely due to the inability of
the arrayCGH technique to detect full tetraploidies [7].
Later on, in the clinical application period, one discordant
result was observed between day-3 arrayCGH and day-5
FISH re-analysis of the remaining cells of the embryo.
Day-3 arrayCGH result was 47, XX, +15, but 22 out of
the 25 cells analysed by day-5 FISH were chromosomally
normal and the remaining three cells were abnormal: two
tetraploid cells and one aneuploid cell (48,XX,+13,+21).
This discordance might result from two main scenarios:
(1) a technical artefact, or (2) a misdiagnosis due to embryo
mosaicism at the cleavage stage if mosaicism was originated
on day-2 and/or day-3 cell divisions and one of the abnor-
mal cells was biopsied.
Therefore, both FISH and arrayCGH techniques have
limitations. In the case of FISH, the major limitation stems
from the limited number of chromosomes that can be ana-
lysed simultaneously; additionally, the technical difficulty of
nuclear fixation can impede diagnosis in some cases. In
arrayCGH, the ability to amplify enough DNA from one
cell had been a major limitation. Improved amplification
protocols, however, have led to amplification rates around
98–99 %. Nonetheless, arrayCGH remains unable to detect
all tetraploid embryos. Some tetraploidies will be detected
(e.g., if they carry an imbalance of sex chromosomes), and
software devices are continuously being implemented to
improve the accuracy of tetraploidy detection. In our pre-
clinical study, the error rate due to this limitation was 2.7 %,
but the number of samples analysed was very low. Further,
some types of polyploid embryos are more prone to arrest
during preimplantation development [21], and therefore
would not have been selected for transfer. In fact, the tetra-
ploid embryo diagnosed as euploid by day-4 arrayCGH in
our study was arrested. Taking into account all these aspects,
the estimated misdiagnosis rate due to non-detection of a
polyploidy is below 0.2 % [7].
Day-3 arrayCGH results of the clinical application
phase showed aneuploidies involving all chromosomes.
Importantly, 28.0 % of the embryos analysed would
have been diagnosed as normal by FISH using our 9-
chromosome panel (chromosomes 13, 15, 16, 17, 18, 21, 22,
X, and Y). The number of abnormal embryos detected by
arrayCGH was 74.3 %, and 63.7 % of the cycles had euploid
embryos for transference. Moreover the higher pregnancy rate
per transfer was achieved in patients over 40 years old, prob-
ably reflecting that in older patients the main problem to
obtain a healthy baby at home is their higher risk of producing
aneuploid embryos.
In conclusion, this study shows a BAC-based arrayCGH
platform that offers a rapid and standardised method for the
screening of all chromosomes in PGS. Although the false
negative rate could not be detected with this study design,
the false positive rate was 2.4 %. Moreover, good clinical
results were obtained, confirming the usefulness of this plat-
form for single-cell analysis in routine clinical diagnosis.
Despite the limitations of single-cell FISH technology, it has
been shown in this work that the re-analysis of day-5 embryos
by FISH can be used to corroborate if the anomalies observed
at cleavage stage were still present on day-5 embryos.
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